Peptide therapy TikTok claims: separating hype from human data

What did @livenow_longevity actually say?

Dr. Charlie Kame, who runs a concierge longevity clinic in Las Vegas, made a pointed argument: buying peptides from gray-market online sources is dangerous, and physician oversight is non-negotiable. He compared it to amoxicillin, saying you wouldn't "get it from some online guy in China." He then listed the peptides his clinic offers, including BPC-157, CJC-1295, NAD, and "R3 TA" (likely referring to a variant of thymosin alpha), all contingent on a medical evaluation.

The video is, at its core, a clinic advertisement. That doesn't make every point wrong, but it does mean the framing serves a commercial purpose. He isn't delivering a neutral public health message. He's recruiting patients. Keep that context in mind as you read the rest of this.

Does the science back this up?

On the core safety concern, he's on solid ground. The gray-market peptide supply chain has documented contamination and dosing problems, and the research community has flagged this repeatedly.

A 2023 review by Cohen et al. in JAMA Internal Medicine analyzed supplements and research chemicals sold online and found significant labeling inaccuracies, including active compounds absent from labels and undisclosed adulterants. While that review focused on SARMs and prohormones, similar quality-control concerns apply to the unregulated peptide market, where products are often labeled "not for human use" to sidestep FDA oversight while being marketed implicitly for exactly that purpose.

The FDA has repeatedly warned that compounded BPC-157 and TB-500 are not FDA-approved drugs, and that peptides sold as "research chemicals" have no verified manufacturing standards. The physician oversight argument holds up. What doesn't hold up is implying that a clinic prescription automatically solves all quality or efficacy questions. Compounded peptides from 503A/503B pharmacies vary in quality too, and the clinical evidence base for most of these compounds in humans remains thin.

What did they get wrong (or right)?

He got the directional point right: physician evaluation before peptide use is genuinely better than self-medicating with unverified online compounds. That's a defensible position, not a controversial one.

Where he oversimplifies is in the amoxicillin analogy. Amoxicillin is an FDA-approved antibiotic with decades of human clinical trial data, a defined pharmacokinetic profile, and regulatory manufacturing oversight. BPC-157, CJC-1295, and most peptides he named have no FDA approval for human use, limited or no Phase III human trial data, and are dispensed through compounding pharmacies operating under a different regulatory framework entirely. Framing compounded peptides as equivalent in legitimacy to a prescription antibiotic papers over a real gap in the evidence base.

He also doesn't mention that "medically appropriate" is doing a lot of work in his pitch. There are no FDA-cleared indications for most of these compounds in healthy adults seeking longevity optimization. A doctor can prescribe off-label, but patients should understand that's what they're getting.

What should you actually know?

If you're considering peptide therapy, the oversight argument is the strongest thing in this video. The gray-market supply is genuinely uncontrolled. A 2022 analysis published in Drug Testing and Analysis (Brennan et al.) found that a significant proportion of "research peptide" products tested contained incorrect concentrations or undisclosed substances.

However, oversight from a licensed physician does not equal proven efficacy. BPC-157 has shown promising results in rodent models for gut and tendon repair, but human randomized controlled trial data is scarce. A 2022 review by Sikiric et al. in Biomedicines summarized animal findings favorably but acknowledged the absence of large-scale human trials. CJC-1295 combined with ipamorelin has some human pharmacokinetic data on growth hormone pulse amplification, but long-term safety data in healthy aging adults is not established.

NAD precursor therapy, which he also mentions, has the strongest human evidence of the compounds listed, with multiple trials showing increases in blood NAD levels, though clinical outcome data remains mixed. That distinction matters when you're comparing "NAD" to "R3 TA" in the same breath.

• Ask any prescribing clinician which specific compounding pharmacy they use and whether it is 503A or 503B accredited.
• Request to see the certificate of analysis for any compounded peptide before use.
• Understand that most peptides used in longevity clinics are prescribed off-label, not based on FDA-approved indications.
• Gray-market sourcing carries real contamination and dosing risks, but a clinic setting does not guarantee efficacy.